> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 9 Million CytomX Shares Without Seeking To Influence Control
- URL: https://www.bullished.co/state-street-holds-9-million-cytomx-shares-without-seeking-to-influence-control-ef963c0a/
- Published: 2026-11-10T12:11:11.000Z
- Updated: 2026-11-10T12:11:11.000Z
- Description: The passive holding represents 4.1% of the common-stock class as CytomX prepares an approval-supporting cancer study.
- Author: Matteo Parrino
- Tags: SEC Filings, CTMX, Industry: Healthcare

State Street reported about [9 million shares](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000642/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [CytomX Therapeutics](https://www.bullished.co/tag/ctmx/), which develops cancer treatments designed to activate mainly inside tumors, in a passive ownership disclosure filed Tuesday. The holding represents 4.1% of the common-stock class, and State Street certified that it was acquired and held without seeking to change or influence control.

## A Passive 4.1% Holding

State Street's exact holding was 9,025,855 shares, measured as of [September 30, 2026](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000642/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co). The 4.1% figure uses the disclosure's beneficial-ownership basis rather than a percentage of shares currently outstanding.

State Street reported shared voting authority over 8,753,246 shares and shared authority to dispose of the full holding. It certified that the securities were bought and held as part of ordinary business activity.

## Varseta-M's Next Clinical Step

CytomX anticipates beginning a Varseta-M study intended to support regulatory approval in the [first half of 2027](https://seekingalpha.com/news/4668496-cytomx-anticipates-varseta-m-registrational-study-in-1h-2027-while-projecting-cash-runway?ref=bullished.co). The company expects its funding to last into the [second half of 2028](https://seekingalpha.com/news/4668496-cytomx-anticipates-varseta-m-registrational-study-in-1h-2027-while-projecting-cash-runway?ref=bullished.co).

Its PROBODY platform masks biologic drugs to concentrate their activation in tumors rather than healthy tissue. CytomX's clinical programs are in early-stage trials: varsetatug masetecan, an antibody carrying a cancer-killing drug for colorectal cancer, and CX-801, a masked interferon alpha-2b treatment being tested in advanced melanoma.

CytomX also works with Bristol Myers Squibb and Regeneron on treatments that engage T cells, and lists alliances with Amgen, Astellas and Moderna. It aims to advance treatments independently or alongside partners.

State Street's holding is passive; CytomX's next planned clinical milestone is the approval-supporting Varseta-M study.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: CYTOMX THERAPEUTICS INC (CTMX)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000642/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [CytomX anticipates Varseta-M registrational study in 1H 2027 while projecting cash runway into 2H 2028 (NASDAQ:CTMX) | Seeking Alpha](https://seekingalpha.com/news/4668496-cytomx-anticipates-varseta-m-registrational-study-in-1h-2027-while-projecting-cash-runway?ref=bullished.co) — seekingalpha.com

### More on CytomX Therapeutics

- [CytomX Spends $25.2 Million As Revenue Shrinks To $1.7 Million — Cancer Trials Advance](https://www.bullished.co/cytomx-spends-25-2-million-as-revenue-shrinks-to-1-7-million-cancer-trials-advance-5f83042b/)
- [CytomX CEO Promises First Survival Data For Colorectal Cancer Drug In January](https://www.bullished.co/cytomx-ceo-promises-first-survival-data-for-colorectal-cancer-drug-in-january-80230079/)

[All CytomX Therapeutics (CTMX) coverage →](https://www.bullished.co/tag/ctmx/)